23andMe nabbed FDA clearance to market its genetic carrier test directly to consumers, a big win for the company as it continues to get back in the agency's good graces and expand the reach for its genetic tests.
Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression. Read more >>
Denmark's Dako is teaming up with Ono Pharmaceutical to develop a test for Ono and Bristol-Myers Squibb's drug for non-small cell lung cancer (NSCLC), Opdivo, adding to its tally of companion diagnostics partnerships and gaining more ground in the field. Read more >>
POPULAR COMMENT THREADS
RainDance Technologies is moving one step closer to completing its long-awaited IPO, filing plans for a $60 million offering to cash in on a growing market for its next-generation sequencing tools.
Researchers have discovered that a skin sample taken from behind the ear of patients with either Alzheimer's or Parkinson's disease had levels of the protein tau 7 times higher than those without the condition. Those with Parkinson's showed levels of alpha-synuclein protein that were 8 times higher than those in the control group.
Exact Sciences is charting big plans for 2015, increasing its sales efforts and pushing for expanded coverage of its stool-based DNA colon cancer test to grab a bigger market share.
Vigilant Biosciences roped in $5.5 million in a Series B round to support development of its diagnostic system for the early detection of oral cancer, giving the company a boost as it eyes European and stateside approval for its product.
Roche and BioMed X are teaming up to create a diagnostics research group focused on biosensors and nanomaterials such as graphene within BioMed X's open innovation lab in Heidelberg, Germany.
From Our Sister Sites
Smith & Nephew was down 8% on the March 3 news that Stryker now has a massive $2.6 billion authorization available for share repurchases. That's a significant shift in strategy for Stryker, which has been highly acquisitive in the last few years and has long been rumored as a potential buyer for Smith & Nephew.
Amgen just announced the debut of the Neulasta Delivery Kit to automatically deliver the medication for infection prevention among cancer patients about 27 hours after chemotherapy, thereby ensuring compliance with the dosing instructions.